MRNA
Moderna, Inc.
$68.28
+0.84 (+1.25%)
At close · Jul 15
Market Cap
$25.46B
Shares
396,786,259
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.94B
-39.9%
FY2025
Net Income
-$2.82B
+20.8%
FY2025
Gross Margin
55.35%
+0.6pp
FY2025
Operating Margin
-158.13%
-36.2pp
FY2025
Diluted EPS
-$7.26
+21.8%
FY2025
Operating Cash Flow
-$1.87B
+37.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.23B | $1.94B | $3.24B | $6.85B | $19.26B | $18.47B | $803M | $60M | $135.07M | $205.83M | $108.4M | |
| $1.73B | $868M | $1.46B | $4.69B | $5.42B | $2.62B | $8M | $0 | $0 | — | — | |
| $492M | $1.08B | $1.77B | $2.16B | $13.85B | $15.85B | $795M | $60M | $135.07M | — | — | |
| — | 55.35% | 54.76% | 31.47% | 71.88% | 85.83% | 99% | 100% | 100% | — | — | |
| $2.93B | $3.13B | $4.54B | $4.85B | $3.3B | $1.99B | $1.37B | $496M | $454.08M | $410.46M | $274.72M | |
| $979M | $1.02B | $1.17B | $1.55B | $1.13B | $567M | $188M | $110M | $94.25M | $64.72M | $57.45M | |
| $229M | $211M | $185M | $617M | $348M | $232M | $31M | $31M | $24.86M | $20.54M | $15.11M | |
| $865.37M | — | — | — | — | — | — | $605.93M | $548.33M | $475.18M | $332.17M | |
| $5.64B | $5.02B | $7.18B | $11.09B | $9.84B | $5.18B | $1.57B | $606M | $548.33M | — | — | |
| -$3.41B | -$3.07B | -$3.95B | -$4.24B | $9.42B | $13.3B | -$763M | -$546M | -$413.27M | -$269.36M | -$223.77M | |
| — | -158.13% | -121.91% | -61.9% | 48.9% | 71.98% | -95.02% | -910% | -305.97% | -130.87% | -206.44% | |
| -$3.18B | -$2.86B | -$3.76B | -$3.62B | $9.77B | $13.53B | -$732M | -$515M | -$388.4M | -$248.82M | -$208.66M | |
| $296M | $314M | $425M | $421M | $200M | $18M | $25M | $39M | $27.02M | $15.24M | $11.31M | |
| -$22M | -$8M | -$87M | -$124M | -$45M | -$29M | -$6M | -$8M | $1.84M | -$1.88M | -$2.71M | |
| -$3.14B | -$2.77B | -$3.61B | -$3.94B | $9.58B | $13.29B | -$744M | -$515M | -$384.41M | -$256M | -$215.17M | |
| $56M | $54M | -$46M | $772M | $1.21B | $1.08B | $3M | -$1M | $326K | -$80K | $1.04M | |
| -$3.19B | -$2.82B | -$3.56B | -$4.71B | $8.36B | $12.2B | -$747M | -$514M | -$384.73M | -$255.92M | -$216.21M | |
| — | -145.16% | -110.04% | -68.84% | 43.41% | 66.06% | -93.03% | -856.67% | -284.84% | -124.34% | -199.46% | |
| — | — | — | — | — | — | -$747.06M | -$514.02M | -$401.86M | -$269.84M | -$230.31M | |
| -$3.18B | -$2.77B | -$3.45B | -$4.47B | $8.02B | $12.18B | -$746M | -$511M | -$384.9M | -$256.67M | -$216.05M | |
| USD/shares | — | -$7.26 | -$9.28 | -$12.33 | $21.26 | $30.31 | -$1.96 | -$1.55 | — | — | — |
| USD/shares | — | -$7.26 | -$9.28 | -$12.33 | $20.12 | $28.29 | -$1.96 | -$1.55 | — | — | — |
| shares | — | 389M | 384M | 382M | 394M | 403M | 381M | 331M | 81.11M | 64.5M | 60.75M |
| shares | — | 389M | 384M | 382M | 416M | 431M | 381M | 331M | 81.11M | 64.5M | 60.75M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2025: $5.34B in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.54×
EV/EBIT
—
Biotechnology median 26.15×
P/E (TTM)
—
Biotechnology median 7.42×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| United States | $1,199,000,000 | $1,785,000,000 | $1,895,000,000 | $5,150,000,000 | $6,177,000,000 | $764,000,000 | $55,000,000 | $89,075,000 |
| Rest of World | $692,000,000 | $853,000,000 | $3,598,000,000 | $7,298,000,000 | $5,448,000,000 | $6,000,000 | $0 | — |
| Europe | $53,000,000 | $598,000,000 | $1,355,000,000 | $6,815,000,000 | $6,846,000,000 | $33,000,000 | $5,000,000 | — |
| Non Us | — | — | — | — | — | — | — | $45,993,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Product Sales | $1,818,000,000 | $3,109,000,000 | $6,671,000,000 | $18,435,000,000 | $17,675,000,000 | $200,000,000 | $0 | $0 |
| COVID-19 | $1,810,000,000 | $3,084,000,000 | $6,671,000,000 | $18,435,000,000 | — | — | — | — |
| Product And Service Other | $126,000,000 | $127,000,000 | $177,000,000 | $828,000,000 | $796,000,000 | — | — | — |
| Stand Ready Manufacturing Revenue | $80,000,000 | $0 | $0 | — | — | — | — | — |
| Grant | $22,000,000 | $37,000,000 | $94,000,000 | $388,000,000 | $735,000,000 | $529,000,000 | $12,000,000 | $12,556,000 |
| Collaboration Arrangement Including Arrangements With Affiliate | $13,000,000 | $48,000,000 | $83,000,000 | $440,000,000 | $61,000,000 | $74,000,000 | $48,000,000 | — |
| License and Royalty | $11,000,000 | $42,000,000 | $0 | $0 | — | — | — | — |
| RSV | $8,000,000 | $25,000,000 | $0 | $0 | — | — | — | — |
| Collaboration Arrangement | — | — | — | $440,000,000 | $61,000,000 | $74,000,000 | $48,000,000 | $122,512,000 |
Key facts
CIK
1682852
CUSIP
60770K107
13F (30d)
102 filings
80 filers
Visit website
Investor relations